Breaking News

Baxter Acquires AesRx

July 9, 2014

Gains Phase II sickle cell disease drug

Baxter International has acquired AesRx, LLC, a private U.S. biopharma company focused on orphan drug targets. With the acquisition Baxter gains Aes-103, an investigational prophylactic treatment in Phase II development for sickle cell disease (SCD). Baxter made an initial payment and may make additional future payments based on development, regulatory and commercial milestones. Financial details were not disclosed.
 
Early studies indicate the compound may reduce the sickling of red blood cells, which in turn, may reduce sickling-related outcomes such as vaso-occlusive crisis, pain, severe anemia, and fatigue. Aes-103 has received Orphan designation from the FDA and is eligible for the same status in Europe.
 
''With this acquisition, we gain a compound that has the potential to address an extremely high unmet clinical need in a community with inadequate treatment options and no recent major clinical developments,'' said Ludwig Hantson, Ph.D., president of Baxter BioScience. ''This program is complementary to our established experience in hemophilia and supports our goals to raise the bar for care of patients with a range of blood-related disorders.''
 
''By becoming a part of Baxter’s organization, we believe this will provide Aes-103 the needed resources and expertise to complete a robust development and commercialization program,'' said Stephen Seiler, AesRx’s founder and former chief executive officer. ''Baxter has a demonstrated track record in the treatment of hematological orphan diseases and is an ideal company to take this important program forward.''

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Filings Update

    Filings Update

    December 1, 2015
    Roche, Pfizer, Janssen, BMS and more

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016